All News

meeting.audience.3_0.jpg

ACR 2023 – Day 4 Report

Jack Cush, MD

The last day at ACR23 was a ghost town as most left, largely because there was limited programming on the fourth and final day. The main attraction on Day 4 was the late-breaking abstract – oral presentations.  Here’s a list of the late breakers; below, I provide commentary on the ones that caught my attention.

Read Article
Dr. Jack Cush

Canadian Consensus on MSK Ultrasound

Jack Cush, MD

Dr. Jack Cush discusses abstract 0726 presented at the 2023 ACR Convergence meeting in San Diego, CA.

Read Article
RheumNow Podcast square

PMR & Popeye's Spinach (10.6.2023)

Jack Cush, MD

Dr. Jack Cush reviews the big PMR reports from this week along with other journal reports from RheumNow.com.

Read Article
gout podagra inflammed

Gout Flare Prophylaxis - Colchicine or NSAIDs?

Jack Cush, MD

Flare prophylaxis is the standard when initiating urate-lowering therapy (ULT) in patients with gout. A new study suggests that colchicine, more so than non-steroidal anti-inflammatory drug (NSAID) prophylaxis, may increase the odds of adverse events, when initiating allopurinol for gout.

Read Article
RheumNow Podcast square

RheumNow Podcast – with Special Guest Dr. Kathryn Dao (9.29.2023)

Jack Cush, MD

This week on the podcast, Dr. Jack Cush is joined by special guest, Dr. Kathryn Dao to review the news and journal reports from the past week on RheumNow.com. They discuss unmet needs in gout, obesity and CV disease in PsA and should you check ANCA antibodies in SLE?

Read Article
gout.MTP1_.jpg

What Changed FDA's Mind About Ilaris for Gout?

MedPage Today

The FDA quietly approved the interleukin (IL)-1 inhibitor canakinumab (Ilaris) for gout 10 days ago, with no announcement from either the agency or the drug's manufacturer, Novartis -- leaving outsiders to guess at what changed in the dozen years since the company's first attempt to gain app

Read Article
RheumNow Podcast square

RheumNow Podcast – with Special Guest Dr. Janet Pope (9.8.2023)

Jack Cush, MD

This week, Dr. Jack Cush reviews the news with special guest, Dr. Janet Pope. They discuss "Not-non-Inferior", large scale genetic screening, Zoster risk w/ newer lupus drugs, tapering, RA referral problems and the TNR webinar session on "ORAL Surveillance Revisited".

Read Article
RheumNow Podcast square

Hard Decisions in RA (9.1.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".

Read Article
FDA.approved.jpg

FDA Approves Canakinumab for Gout Flares

Medscape

The US Food and Drug Administration (FDA) has approved canakinumab (Ilaris) for the treatment of gout flares in adults who cannot be treated with NSAIDs, colchicine, or repeated courses of corticosteroids. The drug is also indicated for people who could not tolerate or had an inadequate response to NSAIDs or colchicine.

Read Article
AR882 a novel and selective URAT1 inhibitor is a safe, efficacious sUA lowering, tophus resolution and with a 68% decrease in total urate crystal volume of the feet and ankles after AR882 75 mg once daily for 6 months. Keenan R, Abst#L15 #ACR23 @RheumNow https://t.co/gMCcSI1v9W https://t.co/lk3XQCaw0A
Dr. Antoni Chan  ( View Tweet)
In case you missed it! AR882-selective oral URAT1i added to #allopurinol rapidly improves/dissolve #tophi. Given with #colchicine, #placebo 3/4 flared vs <1/2 w drug. My critique is why not optimize allopurinol dose - only 300 mg, no fuboxastat L15 #ACR23 @RheumNow @ACRheum https://t.co/NZWLpWXT51
Janet Pope  ( View Tweet)
US adults with #gout had higher 10-year all-cause mortality rates than those without Premature mortality in gout ➡️Has not improved over time despite improved survival in the general population ➡️Worse among women ➡️Worse among Black individuals #ACR23 👉🏽https://t.co/NDCIhKfCNL https://t.co/uKCswHKU0n
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
Who uses #cannabis in #rheumatic #diseases? Those who smoke, have higher pain, more anxiety, poor sleep are more likely to have used cannabis for their rheumatic disease. Half of the >2900 respondents have tried #cannabis. Use of #biologics reduced use. #980 @RheumNow @ACRheum https://t.co/DQDRQN40zR
Janet Pope  ( View Tweet)
McCormick et al. No improvement in premature mortality gap in gout over time. 19% increased mortality in gout. Independent of serum urate and CV risk factors. Abstr#2428 #ACR23 @RheumNow https://t.co/lSoEvajN3O https://t.co/uWNokm7LCT
Richard Conway  ( View Tweet)
Gout mortality A#2428 #ACR23 @RheumNow 1988-1994 (early) v 2007-2016 (late): Has not improved over time Independent of serum uric acid Female gout: increased mortality Black gout pts also increased Conclusion: the inflammation, not the uric acid is the risk https://t.co/LTFoSFzaBu
Eric Dein  ( View Tweet)
#ACR23 #SGLT2 inhibitors assoc with ⬇️ urate ⬇️ flares if #gout ⬇️mortality impact on #metabolicSyndrome ✅ https://t.co/ZIqDqirqar

Dr Gurdeep S Dulay  ( View Tweet)

Join us tonight at 6pm PT/ 9pm ET for our daily #ACR23 recap. https://t.co/0RDwTdzhwS
Dr. John Cush RheumNow ( View Tweet)
Registration is now open! Early bird pricing is available until 11/30/23. See you there! https://t.co/zjXyldwlyl https://t.co/CpQ00745c1

Links:

Dr. John Cush RheumNow ( View Tweet)
Gout Flare Prophylaxis - Colchicine or NSAIDs? A new study suggests that colchicine, more so than non-steroidal anti-inflammatory drug (NSAID) prophylaxis, may increase the odds of adverse events, when initiating allopurinol for gout. https://t.co/MfVvBy0DsD https://t.co/jP5oiAHaBa

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective EHR study of 7,970 gout pts from Singapore finds ~28% are poorly controlled, with only 46% prescribed allopurinol (13% @doses ≥300). Poor control assoc w/ male gender (adj OR 1.66), Malay ethnicity (aOR 1.27), CHF (aOR, 1.64) https://t.co/M8dJFIbZEV https://t.co/aUnLgUmvXN

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×